Loading
A phase 3 trial of IBI363, Bevacizumab in colorectal cancer, run by Innovent Biologics (Suzhou) Co. Ltd., now recruiting.
IBI363 Combined With Bevacizumab for Advanced Colorectal Cancer is a phase 3 interventional study registered as NCT07722494 by Innovent Biologics (Suzhou) Co. Ltd., with 550 participants planned, started 2026-07-31 and due to reach its primary completion in 2028-10-31. Interventions recorded: IBI363 + bevacizumab, Investigator's choice of therapy. Conditions listed: Colorectal Cancer. No results are recorded here; the registry entry is the source.
Shares IBI363, Innovent Biologics, Colorectal cancer.
Shares IBI363, Innovent Biologics.
Shares IBI363, Innovent Biologics.
Shares Innovent Biologics, Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies.
Shares IBI363, Innovent Biologics.
Shares IBI363, Innovent Biologics.
Shares Innovent Biologics, Bevacizumab, Anti-angiogenic therapy.
Shares Innovent Biologics, Monoclonal antibodies, Colorectal cancer.